Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, ...
Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...
“Patients treated with the venetoclax-obinutuzumab combination showed a statistically significant sustained prolongation of PFS compared with patients treated with chlorambucil-obinutuzumab (76.2 vs ...
Four-year follow-up data from a phase II study evaluating obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL) were presented at ...
Use of the targeted therapy combination of venetoclax plus obinutuzumab for fit patients with chronic lymphocytic leukemia (CLL) significantly improved progression-free survival (PFS) at 3 years ...
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA The rates of complete ...
This guidance updates and replaces NICE technology appraisal guidance 663 on venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia, which was available through the Cancer Drugs Fund ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax demonstrated a statistically ...
Venetoclax plus obinutuzumab can be used, within its marketing authorisation, as an option for untreated chronic lymphocytic leukaemia (CLL) in adults. It can only be used if the companies provide the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results